<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03193541</url>
  </required_header>
  <id_info>
    <org_study_id>Rosser-2015-8</org_study_id>
    <nct_id>NCT03193541</nct_id>
  </id_info>
  <brief_title>A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer</brief_title>
  <official_title>A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles Rosser</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To improve upon the non-invasive detection of BCa by further validating a multiplex ELISA
      assay directed at a BCa-associated diagnostic signature in voided urine samples of patients
      with microscopic hematuria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hematuria is the most common presentation of BCa with 8% of patients with microscopic
      hematuria harboring BCa. VUC is the most widely used urine-based assay for detecting BCa;
      however, it fails to detect approximately 50% of low-grade or early stage BCa when it is most
      curable. Because of this severe limitation, patients with hematuria will undergo an invasive
      examination of the urinary bladder, where a miniature camera is inserted into the bladder.

      We propose to improve the non-invasive detection of BCa by further validating a multiplex
      ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of
      patients with microscopic hematuria.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2016</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity of multiplex ELISA assay will be confirmed by cystoscopy.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of multiplex ELISA assay will be compared to VUC and NMP-22 BladderChek.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Bladder Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine collection (minimal 50 mL) and cystoscopy (+ biopsy w/in 4 weeks, if abnormal noted)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults, age 18 and older who have documented microscopic hematuria within the past 3 months
        who are referred for cystoscopy and are willing to participate
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Have documented or reported microscopic hematuria within 3 month of study enrollment

          -  Willing and able to give written informed consent

        Exclusion Criteria (participants must not):

          -  Have history of BCa

          -  History of previous cancer (excluding basal and squamous cell skin cancer)

          -  Have a known active urinary tract infection or urinary retention

          -  Have active stone disease (renal or bladder) or renal insufficiency (creatinine &gt;2.0
             mg/dL)

          -  Have ureteral stents, nephrostomy tubes or bowel interposition

          -  Have recent genitourinary instrumentation (within 10 days prior to signing consent)

          -  Be unable or unwilling to complete the hematuria evaluation (i.e., cystoscopy and
             upper tract imaging)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Charles Rosser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles Rosser, MD</last_name>
    <phone>310-423-5609</phone>
    <email>charles.rosser@cshs.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Oppenheim</last_name>
      <phone>310-423-3713</phone>
      <email>Amy.Oppenheim@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Charles Rosser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 17, 2017</study_first_submitted>
  <study_first_submitted_qc>June 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Charles Rosser</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Hematuria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

